March 24, 2017
Mar 24, 2017
Accel Biotech, a Ximedica company, will be exhibiting at the American Association for Cancer Research (AACR) Annual Meeting from April 1-5, 2017 in Washington, DC.
Accel will be displaying an example of their work in the oncology space, ApoCell’s ApoStream system.
Advances in technology are putting circulating tumor cells (CTCs) at the forefront of cancer research. The ApoStream enables molecular and biological investigation of these CTCs.
Visit booth #1056 at the AACR Annual Meeting to see the instrument and learn more about Accel’s collaboration in the system design.
About Accel Biotech
Accel Biotech, located in Northern California’s Silicon Valley, is a full-service contract development and manufacturing firm. Our mission at Accel Biotech is to pair our unique breadth of engineering and design experience in diagnostics, life sciences and disposables with a passion for quick development. We enable rapid prototyping with in-house machining, 3D printing and full production runs for complex devices. We value customer satisfaction above all else, seeking long-lasting relationships with our clients.
ApoCell focuses its efforts on the identification and analysis of biomarkers in rare circulating cells. They use both standard and proprietary platforms to isolate and enrich cell populations of interest, especially circulating tumor cells (CTCs) and circulating endothelial cells (CECs), as well as additional rare cell types including stem cells.